Reports from University of Pennsylvania Describe Recent Advances in Adverse Drug Reactions (Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation an Analysis of the Sts-intermacs …): Drugs and Therapies – Adverse Drug Reactions

2022 MAR 07 (NewsRx) -- By a News Reporter-Staff News Editor at Health Policy and Law Daily -- Investigators discuss new findings in Drugs and Therapies - Adverse Drug Reactions. According to news originating from Philadelphia, Pennsylvania, by NewsRx correspondents, research stated, “Due to the high cost of left ventricular assist device (LVAD) therapy, payer type may be an important factor in determining eligibility. How payer type influences outcomes after LVAD implantation is unclear.”

Financial supporters for this research include Leonard Davis Institute of Health Economics at the University of Pennsylvania, NIH National Heart Lung & Blood Institute (NHLBI).

Our news journalists obtained a quote from the research from the University of Pennsylvania, “We, therefore, aimed to study the association of health insurance payer type with outcomes after durable LVAD implantation. Using STS-INTERMACS (Society of Thoracic Surgeons-Interagency Registry for Mechanically Assisted Circulatory Support), we studied nonelderly adults receiving a durable LVAD from 2016 to 2018 and compared all-cause mortality and postindex hospitalization adverse event episode rate by payer type. Multivariable Fine-Gray and generalized linear models were used to compare the outcomes. Of the 3251 patients included, 26.0% had Medicaid, 24.9% had Medicare alone, and 49.1% had commercial insurance. Compared with commercially insured patients, mortality did not differ for patients with Medicaid (subdistribution hazard ratio, 1.00 [95% CI, 0.75-1.34], P=0.99) or Medicare (subdistribution hazard ratio, 1.09 [95% CI, 0.84-1.41], P=0.52). Medicaid was associated with a significantly lower adjusted incidence rate (incidence rate ratio, 0.88 [95% CI, 0.78-0.99], P=0.041), and Medicare was associated with a significantly higher adjusted incidence rate (incidence rate ratio, 1.16 [95% CI, 1.03-1.30], P=0.011) of adverse event episodes compared with commercially insured patients. All-cause mortality after durable LVAD implantation did not differ significantly by payer type.”

According to the news editors, the research concluded: “Payer type was associated with the rate of adverse events, with Medicaid associated with a significantly lower rate, and Medicare with a significantly higher rate of adverse event episodes compared with commercially insured patients.”

This research has been peer-reviewed.

For more information on this research see: Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation an Analysis of the Sts-intermacs Registry. Circulation Heart Failure, 2021;14(5):529-538. Circulation Heart Failure can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

The news correspondents report that additional information may be obtained from Sameed Ahmed M. Khatana, University of Pennsylvania, Division of Cardiovascular Medicine, Perelman School of Medicine, 3400 Civ Ctr Blvd, Philadelphia, PA 19104, United States. Additional authors for this research include Thomas C. Hanff, Ashwin S. Nathan, Elias J. Dayoub, Alexander C. Fanaroff, Jay Giri, Peter W. Groeneveld, E. Wilson Grandin and J. Eduardo Rame.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1161/CIRCHEARTFAILURE.120.008277. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)